Abstract

BackgroundThe role of disulfide bond remodeling in HIV-1 infection is well described, but the process still remains incompletely characterized. At present, the data have been predominantly obtained using established cell lines and/or CXCR4-tropic laboratory-adapted virus strains. There is also ambiguity about which disulfide isomerases/ reductases play a major role in HIV-1 entry, as protein disulfide isomerase (PDI) and/or thioredoxin (Trx) have emerged as the two enzymes most often implicated in this process.ResultsWe have extended our previous findings and those of others by focusing on CCR5-using HIV-1 strains and their natural targets - primary human macrophages and CD4+ T lymphocytes. We found that the nonspecific thiol/disulfide exchange inhibitor, 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB), significantly reduced HIV-1 entry and infection in cell lines, human monocyte-derived macrophages (MDM), and also phytohemagglutinin (PHA)-stimulated peripheral blood mononuclear cells (PBMC). Subsequent studies were performed using specific anti-PDI or Trx monoclonal antibodies (mAb) in HIV-1 envelope pseudotyped and wild type (wt) virus infection systems. Although human donor-to-donor variability was observed as expected, Trx appeared to play a greater role than PDI in HIV-1 infection of MDM. In contrast, PDI, but not Trx, was predominantly involved in HIV-1 entry and infection of the CD4+/CCR5+ T cell line, PM-1, and PHA-stimulated primary human T lymphocytes. Intriguingly, both PDI and Trx were present on the surface of MDM, PM-1 and PHA-stimulated CD4+ T cells. However, considerably lower levels of Trx were detected on freshly isolated CD4+ lymphocytes, compared to PHA-stimulated cells.ConclusionsOur findings clearly demonstrate the role of thiol/disulfide exchange in HIV-1 entry in primary T lymphocytes and MDM. They also establish a cell-type specificity regarding the involvement of particular disulfide isomerases/reductases in this process and may provide an explanation for differences among previously published studies. More importantly, from an in vivo perspective, the preferential utilization of PDI may be relevant to the HIV-1 entry and establishment of virus reservoirs in resting CD4+ cells, while the elevated levels of Trx reported in the chronic stages of HIV-1 infection may facilitate the virus entry in macrophages and help to sustain high viremia during the decline of T lymphocytes.

Highlights

  • The role of disulfide bond remodeling in HIV-1 infection is well described, but the process still remains incompletely characterized

  • Our results provide critical new information on the role of disulfide isomerases in HIV infection and further support previous observations that thiol/disulfide exchange is required for HIV-1 entry

  • dithiobis(2-nitrobenzoic acid) (DTNB) inhibits R5 Env pseudotyped virus infection in CD4+/CCR5+ cell lines, primary macrophages and peripheral blood mononuclear cells (PBMC) We initially examined the effect of the nonspecific thiol/ disulfide exchange inhibitor, DTNB, on the infection of different cell types by luciferase (Luc) reporter geneencoding HIV-1JR-FL or HIV-1AD8 Env pseudotyped virus particles

Read more

Summary

Introduction

The role of disulfide bond remodeling in HIV-1 infection is well described, but the process still remains incompletely characterized. The majority of studies investigating the effects of disulfide isomerase/reductase inhibitors [16,17,18,19,20,22], specific polyclonal and monoclonal antibodies (Ab) directed against these enzymes [16,18,20], as well as fluorescent microscopy and Western blot analysis of gp120 interactions and/ or reduction of disulfide bonds [20,23,24], imply that PDI is the key enzyme involved in the HIV-1 entry process It has been reported [25] that Trx plays a major role during HIV-1 Env induced fusion, while PDI expression and/or function has a negligible effect. In yet another study [26], it was shown that another member of the Trx superfamily, glutaredoxin-1 (Grx1), can reduce disulfide bonds in both CD4 and gp120, and its inhibition results in reduced HIV-1 infection

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.